PDF(Pubmed)
Abstract：
The blood-brain barrier is critically important for the treatment of both primary and metastatic cancers of the central nervous system (CNS). Clinical outcomes for patients with primary CNS tumors are poor and have not significantly improved in decades. As treatments for patients with extracranial solid tumors improve, the incidence of CNS metastases is on the rise due to suboptimal CNS exposure of otherwise systemically active agents. Despite state-of-the art surgical care and increasingly precise radiation therapy, clinical progress is limited by the ability to deliver an effective dose of a therapeutic agent to all cancerous cells. Given the tremendous heterogeneity of CNS cancers, both across cancer subtypes and within a single tumor, and the range of diverse therapies under investigation, a nuanced examination of CNS drug exposure is needed. With a shared goal, common vocabulary, and interdisciplinary collaboration, the field is poised for renewed progress in the treatment of CNS cancers.
摘要：
血脑屏障对于治疗中枢神经系统（CNS）的原发性和转移性癌症至关重要。患有原发性中枢神经系统肿瘤的患者的临床结果很差，并且在几十年内没有显着改善。随着颅外实体肿瘤患者治疗的改善，CNS转移的发生率呈上升趋势,原因是CNS暴露量不够理想.尽管有最先进的外科护理和越来越精确的放射治疗，临床进展受到向所有癌细胞递送有效剂量的治疗剂的能力的限制。鉴于中枢神经系统癌症的巨大异质性，跨越癌症亚型和单一肿瘤，以及正在调查的各种疗法，需要对CNS药物暴露进行细微差别检查.有一个共同的目标，常用词汇,和跨学科合作，该领域有望在中枢神经系统癌症的治疗方面取得新的进展。
